Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related Pathway
Open Access
- 1 March 2010
- journal article
- retraction
- Published by Elsevier BV in Journal of Biological Chemistry
- Vol. 285 (13), 10064-10077
- https://doi.org/10.1074/jbc.m109.095208
Abstract
No abstract availableThis publication has 80 references indexed in Scilit:
- TRAF2 Suppresses Basal IKK Activity in Resting Cells and TNFα Can Activate IKK in TRAF2 and TRAF5 Double Knockout CellsJournal of Molecular Biology, 2009
- Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndromeOncogene, 2009
- Is NF-κB a good target for cancer therapy? Hopes and pitfallsNature Reviews Drug Discovery, 2009
- ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemiaOncogene, 2008
- Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage ControlMolecular Cell, 2008
- NF-κB and cancer—identifying targets and mechanismsCurrent Opinion in Genetics & Development, 2008
- Shared Principles in NF-κB SignalingCell, 2008
- Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitorProceedings of the National Academy of Sciences of the United States of America, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Nuclear factor-κB in cancer development and progressionNature, 2006